Valuation: Tengion, Inc.

Market Cap 110K 94.79K 89.19K 81.06K 152K 10.52M 155K 1.05M 410K 5.26M 412K 403K 17.52M P/E 2012
-0.14x
P/E 2013 -0.05x
Enterprise Value 5.55M 4.8M 4.51M 4.1M 7.71M 532M 7.83M 52.92M 20.74M 266M 20.84M 20.39M 886M EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
1 week 0
Extreme 1.0E-5
0
1 month 0
Extreme 1.0E-5
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0.02
10 years 0
Extreme 1.0E-6
0.04
Change 5-day change 1-year change 3-year change Capi.($)
+900.00%0.00% - - 402
+3.22%-1.39%-40.75%-42.74% 611M
-6.67%-14.00%+94.19% - 396M
-6.41%-6.96%-37.97%-11.61% 137M
-1.39%-7.39%-12.35%+40.13% 85.11M
Average +177.75%-6.85%+0.78%-4.74% 245.73M
Weighted average by Cap. -1.36%-7.04%+5.03%-29.16%

Financials

2012 2013
Net sales - -
Net income -16.93M -14.62M -13.76M -12.5M -23.52M -1.62B -23.86M -161M -63.24M -811M -63.56M -62.18M -2.7B -18.93M -16.35M -15.38M -13.98M -26.29M -1.81B -26.68M -180M -70.71M -907M -71.06M -69.52M -3.02B
Net Debt 3.73M 3.22M 3.03M 2.76M 5.19M 358M 5.26M 35.58M 13.95M 179M 14.02M 13.71M 596M 5.44M 4.7M 4.42M 4.02M 7.56M 521M 7.67M 51.87M 20.33M 261M 20.43M 19.99M 869M
Logo Tengion, Inc.
Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Employees
26
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. TNGNQ Stock